These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 20492875)
41. Long-term etanercept use for severe generalized psoriasis in an HIV-infected individual: a case study. Lee ES; Heller MM; Kamangar F; Park KK; Koo JY J Drugs Dermatol; 2012 Mar; 11(3):413-4. PubMed ID: 22395596 [TBL] [Abstract][Full Text] [Related]
42. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502 [TBL] [Abstract][Full Text] [Related]
44. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis. Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955 [TBL] [Abstract][Full Text] [Related]
45. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. Goldsmith DR; Wagstaff AJ Am J Clin Dermatol; 2005; 6(2):121-36. PubMed ID: 15799687 [TBL] [Abstract][Full Text] [Related]
46. Etanercept for the treatment of psoriasis: combination therapy with other modalities. Strober BE; Clarke S J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161 [TBL] [Abstract][Full Text] [Related]
47. Etanercept therapy for psoriasis in a patient with numerous comorbidities. De Simone C; Carbone A; Caldarola G Am J Clin Dermatol; 2010; 11 Suppl 1():49-50. PubMed ID: 20586510 [TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Strober BE; Crowley JJ; Yamauchi PS; Olds M; Williams DA Br J Dermatol; 2011 Sep; 165(3):661-8. PubMed ID: 21574984 [TBL] [Abstract][Full Text] [Related]
49. [Efficacy of TNF-alpha antagonists for plaque-type psoriasis: a systematic review and graphical presentation]. Levy-Roy A; Porcher R; de Fonclare AL; Morel P; Dupuy A Ann Dermatol Venereol; 2009 Apr; 136(4):315-22. PubMed ID: 19361697 [TBL] [Abstract][Full Text] [Related]
50. [Treatment of moderate-severe psoriasis with etanercept in patients with chronic human immunodeficiency virus infection]. Barco D; Puig L; Alomar A Actas Dermosifiliogr; 2010 May; 101 Suppl 1():77-81. PubMed ID: 20492885 [TBL] [Abstract][Full Text] [Related]
51. Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation. Arcese A; Aste N; Bettacchi A; Camplone G; Cantoresi F; Caproni M; D'Amico D; Fabbri P; Filosa G; Galluccio A; Hansel K; Lisi P; Micali G; Musumeci ML; Nicolini M; Parodi A; Patania M; Pezza M; Potenza C; Richetta A; Simonacci M; Trevisan P; Valenti G; Calvieri S Clin Drug Investig; 2010; 30(8):507-16. PubMed ID: 20586516 [TBL] [Abstract][Full Text] [Related]
52. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Bansback N; Sizto S; Sun H; Feldman S; Willian MK; Anis A Dermatology; 2009; 219(3):209-18. PubMed ID: 19657180 [TBL] [Abstract][Full Text] [Related]
53. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Weinberg JM Clin Ther; 2003 Oct; 25(10):2487-505. PubMed ID: 14667953 [TBL] [Abstract][Full Text] [Related]
54. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. Tobin AM; Kirby B BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217 [TBL] [Abstract][Full Text] [Related]
55. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Mease PJ; Goffe BS; Metz J; VanderStoep A; Finck B; Burge DJ Lancet; 2000 Jul; 356(9227):385-90. PubMed ID: 10972371 [TBL] [Abstract][Full Text] [Related]
56. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept]. Mahiques L; Pitarch G; Sánchez-Carazo JL; Pérez-Ferriols A; Soriano CJ; Alegre V Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428 [TBL] [Abstract][Full Text] [Related]
57. Etanercept at different dosages in the treatment of generalized pustular psoriasis: a case series. Esposito M; Mazzotta A; Casciello C; Chimenti S Dermatology; 2008; 216(4):355-60. PubMed ID: 18285687 [TBL] [Abstract][Full Text] [Related]
58. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R; Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365 [TBL] [Abstract][Full Text] [Related]
59. A randomized trial of etanercept as monotherapy for psoriasis. Gottlieb AB; Matheson RT; Lowe N; Krueger GG; Kang S; Goffe BS; Gaspari AA; Ling M; Weinstein GD; Nayak A; Gordon KB; Zitnik R Arch Dermatol; 2003 Dec; 139(12):1627-32; discussion 1632. PubMed ID: 14676082 [TBL] [Abstract][Full Text] [Related]
60. Etanercept therapy in patients with psoriasis and concomitant HCV infection. Garavaglia MC; Altomare G Int J Immunopathol Pharmacol; 2010; 23(3):965-9. PubMed ID: 20943071 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]